(BCAB) Bioatla - Ratings and Ratios
Antibody-Drug Conjugates, T-Cell Therapies, Cancer
BCAB EPS (Earnings per Share)
BCAB Revenue
Description: BCAB Bioatla
BioAtla, Inc. is a clinical-stage biopharmaceutical company specializing in the development of targeted antibody-based therapeutics for the treatment of various solid tumor cancers. The companys innovative approach focuses on conditionally active biologics (CABs) that are designed to remain inactive until they reach the tumor site, thereby minimizing side effects and enhancing therapeutic efficacy.
The companys pipeline includes several promising candidates, such as mecbotamab vedotin (BA3011), an antibody-drug conjugate (ADC) targeting undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC), and ozuriftabmab vedotin (BA3021), another ADC aimed at treating melanoma and squamous cell carcinoma of the head and neck. Other notable candidates in development include Evalstotug (BA3071), a CAB anti-CTLA-4 antibody for various cancers, BA3182, a bispecific candidate for adenocarcinomas, and BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on multiple solid tumors.
From a technical analysis perspective, the stocks current price is $0.38, below its 20-day simple moving average (SMA) of $0.45, indicating a potential downtrend. However, the 50-day SMA is at $0.38, suggesting a possible stabilization. The average true range (ATR) of $0.05 indicates a relatively high volatility of 12.84%. Given the current technical indicators, a potential support level is seen around the 52-week low of $0.27, while resistance is near the 52-week high of $2.37.
Fundamentally, BioAtlas market capitalization stands at $25.04M USD, with no P/E ratio due to the companys current lack of profitability, reflected in its negative return on equity (RoE) of -357.92%. The absence of earnings makes traditional valuation challenging, but the companys progress in its clinical-stage pipeline could be a significant driver for future growth.
Forecasting BioAtlas stock performance involves analyzing both technical and fundamental data. Given the current downtrend and high volatility, a cautious approach is warranted. If the company successfully advances its pipeline candidates through clinical trials, particularly mecbotamab vedotin and ozuriftabmab vedotin, this could positively impact the stock. A potential price target could be near the 52-week high of $2.37 if the company achieves significant milestones, such as positive trial results or FDA approvals. However, failure to advance its pipeline could lead to further decline towards the 52-week low of $0.27. Therefore, investors should closely monitor the companys clinical updates and adjust their strategies accordingly.
Additional Sources for BCAB Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
BCAB Stock Overview
Market Cap in USD | 24m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Biotechnology |
IPO / Inception | 2020-12-16 |
BCAB Stock Ratings
Growth Rating | -86.9 |
Fundamental | - |
Dividend Rating | 0.0 |
Rel. Strength | -66.4 |
Analysts | 4.25 of 5 |
Fair Price Momentum | 0.15 USD |
Fair Price DCF | - |
BCAB Dividends
Currently no dividends paidBCAB Growth Ratios
Growth Correlation 3m | 16.5% |
Growth Correlation 12m | -79.6% |
Growth Correlation 5y | -93.5% |
CAGR 5y | -61.79% |
CAGR/Max DD 5y | -0.62 |
Sharpe Ratio 12m | -1.29 |
Alpha | -96.72 |
Beta | 2.590 |
Volatility | 101.53% |
Current Volume | 492.3k |
Average Volume 20d | 505k |
Stop Loss | 0.4 (2.6%) |
As of July 09, 2025, the stock is trading at USD 0.39 with a total of 492,263 shares traded.
Over the past week, the price has changed by -0.74%, over one month by -23.56%, over three months by +45.52% and over the past year by -69.44%.
No, based on ValueRay´s Analyses, Bioatla (NASDAQ:BCAB) is currently (July 2025) a stock to sell. It has a ValueRay Growth Rating of -86.88 and therefor a clear technical negative rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BCAB is around 0.15 USD . This means that BCAB is currently overvalued and has a potential downside of -61.54%.
Bioatla has received a consensus analysts rating of 4.25. Therefore, it is recommended to buy BCAB.
- Strong Buy: 2
- Buy: 1
- Hold: 1
- Sell: 0
- Strong Sell: 0
According to our own proprietary Forecast Model, BCAB Bioatla will be worth about 0.2 in July 2026. The stock is currently trading at 0.39. This means that the stock has a potential downside of -53.85%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 8.3 | 2035.9% |
Analysts Target Price | 8.3 | 2035.9% |
ValueRay Target Price | 0.2 | -53.8% |